HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Reply
 
Thread Tools Display Modes
Old 12-13-2007, 10:30 PM   #1
tousled1
Senior Member
 
tousled1's Avatar
 
Join Date: Feb 2006
Location: Acworth, GA
Posts: 2,104
Stem Cells in Breast Cancer

Stem Cells in Breast Cancer

Drug resistance in breast cancer has traditionally been explained by acquired or inherent mutations in tumor cells. However, a growing body of research suggests an alternative hypothesis, that of a subpopulation of drug-resistant cancer "stem cells" which gives rise to and maintains the primary tumor and recurrences. Although controversial, this hypothesis is supported by significant preclinical research validating the existence of a self-renewing tumor cell subpopulation that can repopulate tumor growth from a small number of residual cancer cells. Specific treatment strategies that target these cancer stem cells may allow for more robust clinical outcomes than traditional drugs currently provide, and optimistically may result in a permanent cure.

In Thursday morning's mini-symposium on stem cells in breast cancer, Jenny Chang, MD, and Michael Lewis, PhD, co-moderated an overview of this fascinating and contested topic. Max Wicha, MD, discussed the latest scientific data supporting the existence of the "cancer stem cell" subpopulation, including the use of ALDH (aldehyde dehydrogenase, a known stem cell marker) as a method of identifying cancer stem cells, in addition to the previously reported markers CD-44 and CD-24.

Jeremy Rich, MD, provided a neuro-oncologist's perspective on potential treatment strategies targeting the purported cancer stem cell subpopulation, and recommended that mechanisms of resistance within this group of cells should be targeted, while being sensitive to the potential systemic toxicity inherent in antagonizing any stem cell population.

Finally, Peter Laird, MD, focused on the importance of epigenetics (the mechanisms regulating genetic function) to the understanding of breast cancer, and provided evidence that the transition from a non-cancerous to a cancerous state involves epigenetic modifications. Zach Moore, PhD
__________________
Kate
Stage IIIC Diagnosed Oct 25, 2005 (age 58)
ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2%
Neoadjunct chemo: 4 A/C; 4 Taxatore
Bilateral mastectomy June 8, 2006
14 of 26 nodes positive
Herceptin June 22, 2006 - April 20, 2007
Radiation (X35) July 24-September 11, 2006
BRCA1/BRCA2 negative
Stage IV lung mets July 13, 2007 - TCH
Single brain met - August 6, 2007 -CyberKnife
Oct 2007 - clear brain MRI and lung mets shrinking.
March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra
tousled1 is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 06:07 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter